Sciatica refers to pain that radiates along the path of the sciatic nerve, which passes from lower back through hips to buttocks and down each leg. Typically, sciatica affects only one side of the body. This is often a chronic condition that is managed through the use of analgesics to control the pain and non-steroidal anti-inflammatory drugs (NSAIDS) to decrease inflammation. Sciatica is differentiated depending upon the severity of the pain faced by individuals such as acute sciatica, chronic sciatica, and others.
Acute sciatic is known as recent onset of pain in sciatic nerve for duration of four to eight weeks and pain can be self-managed by individuals through pain medications. In chronic sciatica, symptoms include persistent sciatic nerve pain, which lasts over eight weeks in individuals. There are two other types of sciatica which include alternating sciatica and bilateral sciatica. Alternating sciatica is a condition in which the sciatic nerve pain affects in both the legs alternately and thus may lead to degenerative problems in the sacroiliac joint. Bilateral sciatica is a condition in which the sciatic nerve pain occurs in both the legs together, this type of sciatic is very rare and may occur due to degenerative changes in the vertebrae and/or the disc at several spinal levels.
Increasing prevalence of sciatica is anticipated to drive the growth of global sciatica market over the forecast period. For instance, according to the article published in the Spine Health in December 2019, sciatica is common condition with a lifetime incidence varying from 10% to 40% of the population in the U.S.
- This report provides in-depth analysis of the global sciatica market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global sciatica market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
- Key companies covered as a part of this study include Sorrento Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Jubilant Life Sciences Ltd., Hikma Pharmaceuticals PLC., Mylan N.V., Horizon Therapeutics Plc., Sun Pharmaceutical Industries Ltd., Alkem Labs, SCILEX Pharmaceuticals, Inc., Seikagaku Corporation, Kolon Life Science, Inc., Teijin Limited, and SpineThera, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global sciatica market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global sciatica market
-
- Acute Sciatica
- Chronic Sciatica
- Others
-
- Nonsteroidal Anti-Inflammatory Drugs
- Oral Steroids
- Anticonvulsant Agents
- Tricyclic Antidepressants
- Opioid Analgesics
- Others
-
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Sorrento Therapeutics, Inc.
- Teva Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- Zydus Cadila
- Glenmark Pharmaceuticals Ltd.
- Amneal Pharmaceuticals LLC
- Jubilant Life Sciences Ltd.
- Hikma Pharmaceuticals PLC
- Mylan N.V.
- Horizon Therapeutics Plc
- Sun Pharmaceutical Industries Ltd.
- Alkem Labs
- SCILEX Pharmaceuticals, Inc
- Seikagaku Corporation
- Kolon Life Science, Inc.
- Teijin Limited
- SpineThera, Inc.
